189 related articles for article (PubMed ID: 19943201)
1. Phosphatases as targets for cancer treatment.
Lazo JS; Wipf P
Curr Opin Investig Drugs; 2009 Dec; 10(12):1297-304. PubMed ID: 19943201
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?
McCluskey A; Ackland SP; Gardiner E; Walkom CC; Sakoff JA
Anticancer Drug Des; 2001 Dec; 16(6):291-303. PubMed ID: 12375882
[TBL] [Abstract][Full Text] [Related]
3. American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA.
Mitra AP
IDrugs; 2009 Jun; 12(6):339-41. PubMed ID: 19517310
[No Abstract] [Full Text] [Related]
4. AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 2.
Walker K; Padhiar M
IDrugs; 2010 Jan; 13(1):10-2. PubMed ID: 20024839
[TBL] [Abstract][Full Text] [Related]
5. AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 1.
Walker K; Padhiar M
IDrugs; 2010 Jan; 13(1):7-9. PubMed ID: 20024838
[TBL] [Abstract][Full Text] [Related]
6. American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 2. 18-22 April 2009, Denver, CO, USA.
Gale S; McGee V; Lee W
IDrugs; 2009 Jun; 12(6):335-8. PubMed ID: 19517309
[No Abstract] [Full Text] [Related]
7. American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 1. 18-22 April 2009, Denver, CO, USA.
Gale S; McGee V; Lee W
IDrugs; 2009 Jun; 12(6):331-4. PubMed ID: 19517308
[No Abstract] [Full Text] [Related]
8. Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents.
Sharlow ER; Wipf P; McQueeney KE; Bakan A; Lazo JS
Expert Opin Investig Drugs; 2014 May; 23(5):661-73. PubMed ID: 24625356
[TBL] [Abstract][Full Text] [Related]
9. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
10. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.
Park H; Bahn YJ; Ryu SE
Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739
[TBL] [Abstract][Full Text] [Related]
11. A functional approach to questions about life, death, and phosphorylation.
Bernards R
Cancer Cell; 2005 Jun; 7(6):503-4. PubMed ID: 15950899
[TBL] [Abstract][Full Text] [Related]
12. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
13. Structure-based drug design of new leads for phosphatase research.
Combs AP
IDrugs; 2007 Feb; 10(2):112-5. PubMed ID: 17285463
[TBL] [Abstract][Full Text] [Related]
14. STAT proteins: novel molecular targets for cancer drug discovery.
Turkson J; Jove R
Oncogene; 2000 Dec; 19(56):6613-26. PubMed ID: 11426647
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin Drug Discovery & Diagnostics 2009 - First Annual Conference.
Marblestone JG
IDrugs; 2009 Dec; 12(12):750-3. PubMed ID: 19943215
[TBL] [Abstract][Full Text] [Related]
16. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
Broxterman HJ; Georgopapadakou NH
Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
[TBL] [Abstract][Full Text] [Related]
17. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of phosphatase inhibitors.
Vintonyak VV; Antonchick AP; Rauh D; Waldmann H
Curr Opin Chem Biol; 2009 Jun; 13(3):272-83. PubMed ID: 19410499
[TBL] [Abstract][Full Text] [Related]
19. [Progress in the study of antitumor drug targeting on the Ras signaling pathway].
Zhu YJ; Jiang FC
Yao Xue Xue Bao; 2009 Jan; 44(1):1-10. PubMed ID: 19350814
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
